key: cord-0031759-qa9gk0yf
authors: Pilia, Eros; Alborino, Ettore; Covello, Remo Daniel
title: Does melatonin reduce mortality in COVID-19?
date: 2022-05-18
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2022.103817
sha: 911ff5ac63d8d4c5823f74a12dd6626ef9b94e6f
doc_id: 31759
cord_uid: qa9gk0yf

nan

To the editor: Coronaviruses (CoVs) usually affect the respiratory system of mammals causing mild to severe infections. In the past two decades pathogenic human CoVs with high morbidity and mortality such as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) emerged from animal reservoirs. The current global coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), lead to death over 6 million of people worldwide. It represents a challenge for all healthcare systems and for the countries they have dealt with unprecedented social and economic consequences. [1] Since the COVID-19 pandemic began, numerous drugs have been proposed to treat or prevent COVID-19. Along with the search for new drugs, existing drugs with known pharmacokinetics/dynamics and safety profiles have been repurposed beyond traditional use. In fact, compared to de novo drug discovery, drug repurposing could be an effective research strategy to shorten time and reduce costs. A retrospective cohort study by Karimpour-Razkenari et al. on the effects of melatonin in COVID-19 ICU patients has been recently published in this journal. [2] Authors showed only marginal effect on disease-specific biochemical parameters and a non-statistically significant reduction in mortality in melatonin-receiving group (41%) vs non melatonin-receiving group (72%). Melatonin is a neurohormone released by the pineal gland with a regulatory effect on the circadian rhythm and exogenous melatonin is used to manage sleep disorders. A few reviews have recently pointed out the biological plausibility of melatonin in treating COVID-19 patients because of its wide-ranging effects. Some effects are expected, such as reversing circadian rhythm disruption, chronic stress of social isolation, hospital and ICU stay, control of delirium in frail and critically ill patients, and the prevention/treatment of post-COVID-19 cognitive impairment (long COVID).

[3] Some other effects are less obvious but reflect the known pleiotropic complexity of melatonin: possible antiviral action by interfering with SARS-CoV2/angiotensin-converting enzyme 2 association; antioxidant/anti-inflammatory/immunoregulatory activities; [4] cytoprotective effects on medical conditions such as diabetes, metabolic syndrome and ischemic cardiovascular diseases which are associated to worse outcomes in COVID-19 patients; potential adjuvant of anti-SARS-CoV2 vaccines. New network-based medicine methodologies support the biological plausibility of melatonin in COVID-19 and also the Cleveland Clinic suggested that melatonin, alone or in association with other drugs, may help preventing SARS-CoV2 infection or aid in treating COVID-19. [5] What do randomized controlled trials say about melatonin in COVID-19 and its effect on mortality? We investigated PubMed/Medline, Cochrane Central Register of clinical trials and Clinicaltrials.gov for recently completed or not published studies and we identified three RCTs that reported mortality rates in hospitalized COVID-19 patients receiving melatonin in addition to standard therapy compared to patients treated with standard therapy alone. [6, 7, 8] Even if few events occurred, a reduction in mortality at the longest follow-up available can be observed: 1.3% (2/154) among patients treated with melatonin plus standard therapy compared to 11.1% (16/144) in those that received standard therapy alone. Our pooled analysis of three RCTs, as shown in the forest plot, confirmed a significant reduction in mortality at the longest follow-up available in melatonin-receiving group (risk ratio [RR],0.12; 95% CI=0.03-0.50; p˂0.01; I 2 =7%). [9] (Figure 1 ) It is important to note that all reported RCTs were open-label, single-center, small sample size studies with a short follow-up, evaluating melatonin at different doses in different stages of the disease and with variable exclusion criteria. These limitations should bring caution in interpreting these RCTs and we recommend high quality RCTs with a larger number of patients or to include melatonin in registered adaptive platform trials to better clarify its role in COVID-19 patients. If more evidence about melatonin beneficial effect in COVID-19 is confirmed there will be a further confirmation of the importance of network-based medicine methodologies and artificial intelligence-based approach in the identification of drug treatments. Melatonin could become a low J o u r n a l P r e -p r o o f cost adjuvant in the therapy against SARS-CoV-2 infection available in a short time and rapidly producible.

Weekly epidemiological update on COVID-19

Université de Paris/INSERM COVID-19 Research Collaboration/AP-HP COVID CDR Initiative/Entrepôt de Données de Santé AP-HP Consortium. Melatonin does not reduce mortality in adult hospitalized patients with COVID-19: a multicenter retrospective observational study

Can melatonin reduce the severity of COVID-19 pandemic?

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov

The Effect of Melatonin on Thrombosis, Sepsis and Mortality Rate in COVID-19 Patients

Melatonin effects on sleep quality and outcomes of COVID-19 patients: An open-label, randomized, controlled trial

Efficacy of a Low Dose of Melatonin as an Adjunctive Therapy in Hospitalized Patients with COVID-19: A Randomized, Double-blind Clinical Trial

Review Manager (RevMan) [Computer program]. Version 5.4, The Cochrane Collaboration

Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions.Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.None to declare.

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors.Pilia Eros -writing the paper and performed data analysis Ettore Alborino -data collection Remo Daniel Covellostudy design and writing the paper J o u r n a l P r e -p r o o f

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.You can register any type of research at http://www.researchregistry.com to obtain your UIN if you have not already registered. This is mandatory for human studies only. Trials and certain observational research can also be registered elsewhere such as: ClinicalTrials.gov or ISRCTN or numerous other registries.

Name of the registry:None to declare.

Unique Identifying number or registration ID:None to declare.

Hyperlink to your specific registration (must be publicly accessible and will be checked): None to declare.

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish Pilia Eros Ettore Alborino Remo Daniel Covello